P. Pelegrín
Molecular Biology · 2006–2022
A researcher in the Science corpus: 4 papers; trusts 7 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 82 citations into it; #11,966 of 17,773 by trust here, #7,384 by citations
- Physiology — 14 citations into it; #1,207 of 2,276 by trust here, #1,405 by citations
Whom P. Pelegrín trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts P. Pelegrín overall
Papers from P. Pelegrín's perspective
Ordered by how strongly the researchers P. Pelegrín trusts endorse each paper. Same corpus, a different order for every researcher.
- Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf (Nature)
- Altered Cytokine Production in Mice Lacking P2X7Receptors* (Journal of Biological Chemistry)
- Cryopyrin activates the inflammasome in response to toxins and ATP (Nature)
- Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3 (Nature)
- Molecular physiology of P2X receptors. (Physiological Reviews)
- Pannexin membrane channels are mechanosensitive conduits for ATP (FEBS Letters)
- The P2X7 Receptor: A Key Player in IL-1 Processing and Release1 (Journal of Immunology)
- Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. (Methods)
- RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems (Nature)
- IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. (Immunity)
Their papers
- Pannexin‐1 mediates large pore formation and interleukin‐1β release by the ATP‐gated P2X7 receptor (2006) — 1,479 citations
- The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response (2014) — 777 citations
- The gasdermins, a protein family executing cell death and inflammation (2019) — 1,405 citations
- NLRP3 and pyroptosis blockers for treating inflammatory diseases. (2022) — 639 citations